Trastuzumab is approved for the treatment of HER2-positive breast cancer and gastric cancer.
The recent study showed that HER2 overexpression or amplification is noted about 5-15% of
total biliary tract cancer patients and have shown efficacy in small basket trials. The aim
of this study is to evaluate the efficacy and safety of trastuzumab in the combination of
mFOLFOX for gemcitabine+cisplatin refractory biliary tract cancer patients.
This phase II study is designed to see whether trastuzumab-pkrb+FOLFOX is active as 2nd or
3rd line treatment for HER2-positive biliary tract cancer patients.
HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.